These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30509093)

  • 1. Prognostic value of functional tumor burden on 68Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors.
    Ohnona J; Nataf V; Gauthe M; Balogova S; Belissant Benesty O; Zhang-Yin J; Talbot JN; Montravers F
    Neoplasma; 2019 Jan; 66(1):140-148. PubMed ID: 30509093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas.
    Ambrosini V; Campana D; Polverari G; Peterle C; Diodato S; Ricci C; Allegri V; Casadei R; Tomassetti P; Fanti S
    J Nucl Med; 2015 Dec; 56(12):1843-8. PubMed ID: 26405169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
    Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
    Froeling V; Röttgen R; Collettini F; Rothe J; Hamm B; Brenner W; Schreiter N
    Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
    Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
    Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of a whole-body dynamic 68GA-DOTATOC PET/CT acquisition to differentiate physiological uptake of pancreatic uncinate process from pancreatic neuroendocrine tumor.
    Thuillier P; Bourhis D; Karakatsanis N; Schick U; Metges JP; Salaun PY; Kerlan V; Abgral R
    Medicine (Baltimore); 2020 Aug; 99(33):e20021. PubMed ID: 32871968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.
    Paiella S; Landoni L; Tebaldi S; Zuffante M; Salgarello M; Cingarlini S; D'Onofrio M; Parisi A; Deiro G; Manfrin E; Bianchi B; Montagnini G; Crinò SF; Bassi C; Salvia R
    Neuroendocrinology; 2022; 112(2):143-152. PubMed ID: 33508821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (
    Matsumoto T; Okabe H; Yamashita YI; Yusa T; Itoyama R; Nakao Y; Yamao T; Umzaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Nitta H; Hayashi H; Imai K; Chikamoto A; Baba H
    Surg Today; 2019 Jan; 49(1):21-26. PubMed ID: 30128759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution.
    Acker G; Kluge A; Lukas M; Conti A; Pasemann D; Meinert F; Anh Nguyen PT; Jelgersma C; Loebel F; Budach V; Vajkoczy P; Furth C; Baur ADJ; Senger C
    Neurosurg Focus; 2019 Jun; 46(6):E9. PubMed ID: 31153151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 68Ga-DOTATOC and 18F-FDG PET Predicts a Double Component With Different Grade of a Pancreatic Neuroendocrine Tumor in a Patient With Multiple Endocrine Neoplasia Type 1.
    Paepegaey AC; Gaujoux S; Meyer C; Rouquette A; Libé R
    Clin Nucl Med; 2020 Jun; 45(6):e281-e282. PubMed ID: 32349092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from
    Thuillier P; Liberini V; Grimaldi S; Rampado O; Gallio E; Santi B; Arvat E; Piovesan A; Filippi R; Abgral R; Molinari F; Deandreis D
    J Nucl Med; 2022 Jul; 63(7):1014-1020. PubMed ID: 34740949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
    Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
    Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT and 68Ga-DOTATOC PET/CT in Diffuse Pancreatic Neuroendocrine Tumor.
    Ji X; Dong A; He Q; Dong H; Zuo C
    Clin Nucl Med; 2020 May; 45(5):e245-e248. PubMed ID: 32049733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
    Luboldt W; Hartmann H; Wiedemann B; Zöphel K; Luboldt HJ
    Mol Imaging; 2010 Dec; 9(6):351-8. PubMed ID: 21084031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
    Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
    J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.